Jarrod Ehrie, MD

All Publications

• Behavioral and Functional Neuroimaging Effects of Delivering a Course of Repetitive Transcranial Magnetic Stimulation to Personalized Targets Within the Ventrolateral Or Dorsolateral Prefrontal Cortex in Treatment-Seeking Participants with Cannabis Use Disorder. medRxiv : the preprint server for health sciences McCalley, D., Wong, B., Geoly, A., Struckman, W., Azeez, A., Kaloiani, I., Kim, B., Ninomiya, S., Ehrie, J., Austelle, C. W., Rolle, C. E., Kim, J. P., Froeliger, B., McRae-Clark, A. L., Sahlem, G. L. 2026

  Abstract

  Repetitive Transcranial Magnetic Stimulation (rTMS) is a promising treatment across addictive disorders including Cannabis Use Disorder (CUD). Stimulation of two rTMS-targets, the ventromedial prefrontal cortex (vmPFC) and the left dorsolateral prefrontal cortex (LDLPFC), limbic and executive control network hubs respectively, may yield differential effects. In this pilot trial, we explored the differential effects of 36-sessions of rTMS applied to either the vmPFC or LDLPFC.Treatment-seeking participants with moderate or severe CUD (n=20, 10F, age=33.3±9.8SD) were randomized to 36-sessions of open-label rTMS (two sessions-per-visit, two or three visits-per-week) to either the LDLPFC (3000-pulses; 10Hz) or vmPFC (900-pulses; 1Hz) using personalized functional Magnetic Resonance Imaging (fMRI) targets along with three-sessions of Motivational Enhancement Therapy. At baseline and following rTMS, the Time-Line Follow-Back was used to measure Days-per-week of cannabis use and the fMRI Regulation of Craving (ROC) task was used to measure network activation to cues associated with long-term negative ('Later') and short-term positive ('Now') consequences of cannabis use.Eighty percent of participants completed study-rTMS. There was a significant decrease in days-perweek of cannabis use in both groups (vmPFC: d=7.9; DLPFC, d=3.1) between the four-weeks of baseline and seven-weeks of follow-up. LDPFC-rTMS reduced fMRI BOLD signal magnitude and increased LDLPFC functional connectivity in response to cues, while vmPFC-TMS reduced functional connectivity.Treatment-seeking participants with CUD reduced the number of days-per-week they used cannabis when receiving rTMS applied to either the LDPFC or vmPFC, while fMRI effects differed by treatment target. Future larger sham-controlled trials are needed for efficacy and biomarker determination.

  View details for DOI 10.64898/2026.06.08.26355193

  View details for PubMedID 42326779

  View details for PubMedCentralID PMC13278191

• Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. The American journal of psychiatry Tucciarone, J. M., Bandeira, I. D., Blasey, C., Kratter, I. H., Ehrie, J., Keller, J., Pankow, H., Chang, M., Hawkins, J., Evers, A. G., Bernert, R., DeBattista, C., Truong, H., Rodriguez, C. I., Heifets, B. D., Schatzberg, A. F. 2026: appiajp20250840

  Abstract

  Ketamine rapidly reduces suicidal ideation in major depressive disorder (MDD), but its effects are transient. Preclinical and clinical studies suggest that ketamine's antidepressant and antisuicidal effects may be partly mediated by mu-opioid receptor (MOR) modulation. The authors investigated the efficacy and safety of low-dose sublingual buprenorphine, a partial MOR agonist, as a follow-on treatment to prolong the effects of intravenous ketamine.This was a randomized, double-blind, placebo-controlled trial conducted at a single outpatient center in the United States. Adults with MDD and a total score ≥6 on the Scale for Suicide Ideation (SSI) were randomly assigned in a 1:1 ratio to receive either sublingual buprenorphine (0.2 to 0.8 mg/day) or a matched placebo for 4 weeks, beginning 48 hours after a single open-label intravenous ketamine infusion (0.5 mg/kg over 40 minutes). The primary outcome was the change in SSI total score, assessed weekly from day 1 through day 31.From November 2020 to March 2025, 50 participants (68% female) received ketamine, of whom 45 completed at least 1 week of follow-on treatment. Both groups showed significant reductions in SSI total scores, with greater improvement in the buprenorphine group (mean change, -11.6, SD=5.8; N=23) than the placebo group (mean change, -6.3, SD=7; N=22) (Glass delta=0.76, 95% CI=0.11, 1.39). Mixed-effects modeling showed a significant time-by-treatment interaction (p<0.001). Depression scores did not differ significantly between groups. No serious treatment-related adverse events occurred.This randomized controlled trial provides the first evidence that a pharmacological intervention, buprenorphine, significantly sustains and enhances the antisuicidal effects of ketamine in MDD. These findings offer a potentially scalable and safe therapeutic option for a population at risk of suicide.

  View details for DOI 10.1176/appi.ajp.20250840

  View details for PubMedID 42151794

• How Common Are Incidental Brain MRI Findings in Psychiatric Populations? Insights From Patients Seeking Accelerated TMS Austelle, C., Struckmann, W., Jones, R., Buchanan, D., Lissemore, J., Geoly, A., Feyder, M., Stimpson, K., Ford, T. J., Ehrie, J., Airan, R., Rolle, C., Bentzley, B., Williams, N. ELSEVIER SCIENCE INC. 2026

  View details for Web of Science ID 001765478600009

• Building Inter-Institutional Education in Psychiatric Subspecialties: Experiences from the Interventional Psychiatry Consortium. Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry Green, Y. S., Ailani, S., Ehrie, J., Zabinski, J. 2026

  View details for DOI 10.1007/s40596-026-02338-4

  View details for PubMedID 41957237

• Stanford neuromodulation therapy for treatment-resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy. World psychiatry : official journal of the World Psychiatric Association (WPA) Kratter, I. H., Austelle, C. W., Lissemore, J. I., Wada, M., Geoly, A., Chaiken, A., Kaloiani, I., Johnson, N., Wan, S., Kozyr, L., Makarewycz, E., Wong, B., Sridhar, M., Espil, F. M., Bassano, N., Kim, B., Ehrie, J., Maron-Katz, A., Tischler, C., Nejad, R., Batail, J. M., Phillips, A. L., Cole, E. J., Ford, T. J., Bentzley, B. S., Jo, B., Schatzberg, A. F., Spiegel, D., Rolle, C., Sahlem, G. L., Williams, N. R. 2026; 25 (1): 105-116

  Abstract

  Stanford neuromodulation therapy (SNT) is a rapid-acting, high-dose, intermittent theta-burst stimulation protocol. Although it has previously demonstrated efficacy for treatment-resistant depression (TRD) in a randomized controlled trial (RCT), replication in a larger sample is needed. Additionally, the electrophysiological effects of SNT remain unknown. Here we report results from a new double-blind, sham-controlled RCT along with electroencephalography (EEG) findings from the initial and current trials. In the current RCT, 53 participants with TRD were enrolled, and 48 who continued to meet entry criteria were randomized to receive active (N=24) or sham (N=24) SNT. At 1-month, remission (primary outcome) was achieved in 50.0% of active vs. 20.8% of sham participants (χ2 1,48=4.5, p=0.035), and response (secondary outcome) similarly favored active treatment (54.2% vs. 25.0%; χ2 1,48=4.3, p=0.039). Beta band EEG findings converged across trials: frontal beta power decreased significantly following active but not sham SNT in both the initial pilot study and the current trial. Additionally, beta baseline activity and post-SNT changes related to treatment efficacy in the current study. Specifically, greater post-SNT reduction in left anterior cingulate cortex (L-ACC) beta power correlated with greater clinical improvement immediately (rho=0.48, p=0.019) and 1-month after (rho=0.51, p=0.012) active SNT. Moreover, higher pre-treatment L-ACC beta power predicted greater subsequent clinical benefit from active SNT (immediate-post: β=-10.26, p=0.0042; 1-month after: β=-9.00, p=0.024). Neither of these L-ACC beta power findings was observed with sham stimulation. In sum, this study replicates SNT's therapeutic efficacy, identifies left frontal beta suppression as a potential mechanism of action, and highlights baseline L-ACC beta power as a candidate scalable pre-treatment biomarker of efficacy.

  View details for DOI 10.1002/wps.70032

  View details for PubMedID 41536095

  View details for PubMedCentralID PMC12805067

• LOW DOSE BUPRENORPHINE ENHANCES THE ANTISUICIDAL EFFECTS OF KETAMINE IN MAJOR DEPRESSIVE DISORDER: A RANDOMIZED CONTROLLED TRIAL Bandeira, I. D., Tucciarone, J. M., Blasey, C., Kratter, I. H., Ehrie, J., Keller, J., Pankow, H., Chang, M., Hawkins, J., Evers, A. G., Bernert, R., Debattista, C., Truong, H., Rodriguez, C. I., Heifets, B. D., Schatzberg, A. F. SPRINGERNATURE. 2026

  View details for Web of Science ID 001665758000727

• Evaluating Augmentation of Anti-Suicidal Effects of Intravenous Ketamine by Low Oral Doses of Opioid Receptor Partial Agonism Tucciarone, J., Bandeira, I. D., Kratter, I. H., Ehrie, J., Pankow, H., Chang, M., Hawkins, J., Blasey, C., Heifets, B., Schatzberg, A. ELSEVIER SCIENCE INC. 2025

  View details for Web of Science ID 001469569400015

• Genetics and Schizophrenia CURRENT BEHAVIORAL NEUROSCIENCE REPORTS Seltzberg, H., Ehrie, J., Goldwaser, E. 2024; 11 (2): 57-63

  View details for DOI 10.1007/s40473-024-00274-x

  View details for Web of Science ID 001195729600001

• Hope in the Face of "Futility": Considering the Full Scope of Psychiatric Treatment Options. AJOB neuroscience Austelle, C. W., Ehrie, J., Zabinski, J. S. 2024; 15 (1): 59-61

  View details for DOI 10.1080/21507740.2023.2292496

  View details for PubMedID 38207185

• Transcranial Magnetic Stimulation in the Treatment of Positive, Negative, and Cognitive Symptoms of Psychosis CURRENT BEHAVIORAL NEUROSCIENCE REPORTS Manfredi, N., Zhang, R., Seltzberg, H., Johnson, M., Ehrie, J. 2023

  View details for DOI 10.1007/s40473-023-00262-7

  View details for Web of Science ID 001079831900001

• A Call for Synergy in Psychiatric and Structural Policy, Research, and Intervention PSYCHIATRIC SERVICES Erickson, B. R., Ehrie, J., Goldman, M. L. 2023; 74 (6): 669-670

  View details for DOI 10.1176/appi.ps.20230150

  View details for Web of Science ID 001018867400022

  View details for PubMedID 37259590

  View details for PubMedCentralID PMC10919937

• Development of a student-created internal medicine frameworks website for healthcare trainees DIAGNOSIS Murdock, H., Ehrie, J., Bennett, N. L. L., Kogan, J. R. R. 2023; 10 (3): 313-315

  Abstract

  Describe medical student perspectives on framework learning and develop a free, online, mobile-friendly framework website.Internal medicine clerkship students were surveyed at a single U.S. medical school regarding how they learn frameworks. We used Draw.io to create frameworks, which were edited by expert clinicians. Frameworks were hosted online through an academic server, and Google analytics was used to track website activity.Most medical students report learning frameworks from attending clinicians. We developed 87 frameworks on the "Penn Frameworks'' website, which was visited by 9,539 unique users from 124 countries over three years.Most medical students perceive that they learn frameworks during clinical rotations from attending clinicians. We found that it is feasible to develop a low-cost, expert-curated, mobile-friendly resource to supplement in-person learning.

  View details for DOI 10.1515/dx-2023-0020

  View details for Web of Science ID 000975538900001

  View details for PubMedID 37081721

• A Rapid Review of ?Low-Threshold? Psychiatric Medication Prescribing: Considerations for Street Medicine and Beyond PSYCHIATRIC SERVICES Erickson, B. R., Ehrie, J., Murray, S., Dougherty, R. J., Wainberg, M. L., Dixon, L. B., Goldman, M. L. 2023; 74 (3): 282-291

  Abstract

  No widely accepted clinical guidelines, and scant directly applicable pragmatic research, are available to guide the prescription of psychiatric medications in "low-threshold" outpatient settings, such as street outreach, urgent care, and crisis care, as well as walk-in, shelter, and bridge and transition clinics. Providers frequently prescribe medications in these settings without patients' having firm psychiatric diagnoses and without medical records to guide clinical decision making. Persons who receive medications in these settings often seek help voluntarily and intermittently for mental illness symptoms. However, because of structural and individual factors, such patients may not engage in longitudinal outpatient psychiatric care. The authors reviewed the literature on psychiatric medication prescribing in low-threshold settings and offer clinical considerations for such prescribing.The authors conducted a rapid literature review (N=2,215 abstracts), which was augmented with up-to-date clinical prescribing literature, the authors' collective clinical experience, and DSM-5 section II diagnostic criteria to provide considerations for prescribing medications in low-threshold settings.For individuals for whom diagnostic uncertainty is prominent, a symptom-based diagnostic and treatment approach may be best suited to weigh the risks and benefits of medication use in low-threshold settings. Practical considerations for treating patients with clinical presentations of psychosis and trauma, as well as mood, anxiety, and substance use disorders, in low-threshold settings are discussed.An urgent need exists to invest in pragmatic research and guideline development to delineate best-practice prescribing in low-threshold settings.

  View details for DOI 10.1176/appi.ps.20220196

  View details for Web of Science ID 000972055200010

  View details for PubMedID 36039554

  View details for PubMedCentralID PMC9971341

• Elimination of Routine Screening Laboratory Tests for Psychiatric Admission PSYCHIATRIC SERVICES Erickson, B., Landry, C., Ehrie, J. 2021; 72 (5): 615-616

  View details for DOI 10.1176/appi.ps.72501

  View details for Web of Science ID 000647814500025

  View details for PubMedID 33950747

  View details for PubMedCentralID PMC8819915

• Survey of Addiction Specialists' Use of Medications to Treat Alcohol Use Disorder FRONTIERS IN PSYCHIATRY Ehrie, J., Hartwell, E. E., Morris, P. E., Mark, T. L., Kranzler, H. R. 2020; 11: 47

  Abstract

  Several medications have been shown to be safe and effective for treating alcohol use disorder (AUD); however, these medications are prescribed infrequently. We conducted a survey of the demographics, practice characteristics, and self-perceived knowledge, experience, and opinions of addiction specialists on the use of AUD medications and how to increase their use.We sent a 19-question survey to members of the American Society of Addiction Medicine (ASAM) and the American Academy of Addiction Psychiatry (AAAP).We received a total of 395 responses from ASAM members and 194 responses from AAAP members. One hundred of the respondents were members of both organizations. The large majority of respondents (92.6%) were prescribers, and 81.6% were non-trainee physicians. The two most frequently used medications for treating AUD were oral naltrexone (27%) and long-acting naltrexone (18%). Respondents were significantly more confident in the strength of the research findings and evidence for the efficacy and safety of naltrexone than other AUD medications (p < 0.001 ). Respondents identified additional education to current providers about existing medications as the most important potential intervention to increase the use of AUD medications.Compared with a survey published in 2001, in 2018 the proportion of respondents who reported using naltrexone more than doubled and addiction specialists were more confident in their use of AUD medications, rating their efficacy and safety more highly. Consistent with findings from other recent studies, providing more education to practitioners about existing AUD medications may be the most effective way to increase their use.

  View details for DOI 10.3389/fpsyt.2020.00047

  View details for Web of Science ID 000517545500001

  View details for PubMedID 32116860

  View details for PubMedCentralID PMC7034336

• Unmasking of Previously Asymptomatic Central Venous Stenosis following Percutaneous Transluminal Angioplasty of Hemodialysis Access Ehrie, J. E., Sammarco, T. E., Chittams, J. L., Trerotola, S. O. ELSEVIER SCIENCE INC. 2017: 1409-1414

  Abstract

  To determine the frequency of new-onset symptoms of central venous stenosis (CVS) after percutaneous transluminal angioplasty (PTA) of a hemodialysis access-related stenosis in patients with previously asymptomatic CVS and to identify risk factors for this phenomenon.Retrospective review was performed of patients treated with PTA for an access-related stenosis (excluding central vein interventions) between 2001 and 2016 who returned within 3 months with symptoms of CVS (ie, "unmasking"): 39 patients met these criteria. A control group of 122 patients who had untreated asymptomatic CVS and did not experience unmasking was selected. Fistulograms were graded for degree of CVS. A total of 51% of the unmasked group was male, with an average age of 65 years; 57% of the control group was male, with an average age of 63 years.The incidence of unmasking among patients with untreated asymptomatic CVS was 4.9%. A total of 90% of the unmasked group (35 of 39) had upper-arm access, compared with 77% of the control group (94 of 122; P = .017). A total of 28% of unmasked-group patients (11 of 39) underwent thrombectomy, vs 4% of controls (5 of 122; P < .0001). A total of 54% of unmasked-group patients (21 of 39) had significant brachiocephalic vein stenosis, vs 26% of controls (32 of 122; P = .001). A total of 8% of unmasked-group patients (3 of 39) had superior vena cava stenosis, vs none of the 122 controls (P = .01). A total of 64% of unmasked-group patients (25 of 39) had extensive collateral vessels, vs 24% of controls (29 of 122; P < .0001).The incidence of unmasking of asymptomatic CVS is low. Prophylactic treatment of asymptomatic CVS therefore remains generally inadvisable. However, patients undergoing declotting with extensive collateral vessels might warrant treatment of asymptomatic CVS.

  View details for DOI 10.1016/j.jvir.2017.07.006

  View details for Web of Science ID 000412794400010

  View details for PubMedID 28827013